Brooks Laboratories Limited

NSEI:BROOKS Stock Report

Market Cap: ₹4.2b

Brooks Laboratories Balance Sheet Health

Financial Health criteria checks 6/6

Brooks Laboratories has a total shareholder equity of ₹592.1M and total debt of ₹71.8M, which brings its debt-to-equity ratio to 12.1%. Its total assets and total liabilities are ₹911.2M and ₹319.2M respectively. Brooks Laboratories's EBIT is ₹22.0M making its interest coverage ratio 3. It has cash and short-term investments of ₹8.1M.

Key information

12.1%

Debt to equity ratio

₹71.79m

Debt

Interest coverage ratio3x
Cash₹8.08m
Equity₹592.09m
Total liabilities₹319.16m
Total assets₹911.24m

Recent financial health updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28
Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10
Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08
Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07
Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05
Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22
Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Recent updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28
Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10
Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Feb 22
Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08
Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07
Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05
Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22
Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Financial Position Analysis

Short Term Liabilities: BROOKS's short term assets (₹378.6M) exceed its short term liabilities (₹287.0M).

Long Term Liabilities: BROOKS's short term assets (₹378.6M) exceed its long term liabilities (₹32.2M).

Debt to Equity History and Analysis

Debt Level: BROOKS's net debt to equity ratio (10.8%) is considered satisfactory.

Reducing Debt: BROOKS's debt to equity ratio has reduced from 29.4% to 12.1% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BROOKS has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BROOKS is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 03:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brooks Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research